Share on LinkedInShare on LinkedIn

ARTICLE · 15 JUNE 2005

Parallel Trade in the Pharma Sector: Where Now for Stock Management?

Bristows LLP
Bristows LLP
Contributor
Bristows LLP

Bristows LLP

We are Bristows, the world’s leading specialist law firm for clients that innovate. We are a London...

View firm profile
Explore more from Bristows LLP

The issues raised by the parallel trade of pharmaceuticals are rarely out of the European courts for long. This article considers how competition law currently treats parallel trade by pharmaceutical companies, and looks at likely future developments.

United KingdomAntitrust/Competition Law

Originally published in Partnering Focus

The issues raised by the parallel trade of pharmaceuticals are rarely out of the European courts for long. This article considers how competition law currently treats parallel trade by pharmaceutical companies, and looks at likely future developments.

1. Introduction

The relevant competition rules prohibit two types of conduct: anti-competitive agreements between two or more companies and unilateral action by firms which amounts to an abuse of a dominant position. These rules are found in Articles 81 and 82 of the EC Treaty respectively. Attempts to control parallel trade can infringe either Article 81 or Article 82. The competition authorities in Europe attach great importance to encouraging competition throughout the European single market. Conduct or agreements which threaten to divide that single market are therefore subject to close scrutiny.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from